Targeting specific proteins in triple negative breast cancer
Targeting Neoantigens in Triple Negative Breast Cancer
['FUNDING_R01'] · WASHINGTON UNIVERSITY · NIH-10675496
This study is testing new vaccines designed to help your body fight triple negative breast cancer by targeting special proteins on cancer cells, especially for those who didn't respond well to their first round of chemotherapy, and you might even get a treatment tailored just for you!
Quick facts
| Phase | ['FUNDING_R01'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | WASHINGTON UNIVERSITY (nih funded) |
| Locations | 1 site (SAINT LOUIS, UNITED STATES) |
| Trial ID | NIH-10675496 on ClinicalTrials.gov |
What this research studies
This research focuses on developing vaccines that target neoantigens, which are unique proteins found on cancer cells, specifically in patients with triple negative breast cancer (TNBC) who have not responded fully to initial chemotherapy. The approach involves conducting clinical trials to test the effectiveness of these neoantigen vaccines, both alone and in combination with an immune checkpoint inhibitor called anti-PD-L1. By analyzing the immune response to these vaccines, the research aims to enhance the body's ability to fight cancer. Patients participating in this research may receive personalized treatment based on their specific cancer profile.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients with persistent triple negative breast cancer following neoadjuvant chemotherapy.
Not a fit: Patients with other types of breast cancer or those who have not undergone neoadjuvant chemotherapy may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective immunotherapy options for patients with triple negative breast cancer.
How similar studies have performed: Previous research has shown promise in using neoantigen-targeted therapies in other cancers, indicating potential for success in this approach for breast cancer.
Where this research is happening
SAINT LOUIS, UNITED STATES
- WASHINGTON UNIVERSITY — SAINT LOUIS, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: GILLANDERS, WILLIAM E. — WASHINGTON UNIVERSITY
- Study coordinator: GILLANDERS, WILLIAM E.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Conditions: Breast Cancer, Cancers